Abstract
Introduction
Once considered a marginal event, the crucial role of neuroinflammation in the onset and progression of many neurodegenerative diseases is now clear [1] [2] [3] . Acute neuroinflammatory responses are generally beneficial to the central nervous system (CNS), because they tend to minimize further injury and contribute to the repair of the damaged tissue. In contrast, when glial activation inappropriately persists long after the initial injury or insult, the prolonged condition of neuroinflammation induces profound changes in the pathophysiological significance of the glial reaction so that inflammation, from a defensive response, may inexorably turn into a detrimental process [4, 5] . Indeed, chronic neuroinflammation implicates protracted activation of both microglial and astroglial cells, with the consequent sustained release of proinflammatory molecules [6, 7] . In this context, the role of microglia has been extensively described; however, the astrocyte involvement remains to be better elucidated. After [8] [9] [10] . Although phagocytic glia initially engulfs and degrades A␤, it then, however, loses its capability and prolonged glial activation results in an increased release of chemokines and damaging cytokines [11] . Moreover, glial cells express receptors for advanced glycation end-products, which bind A␤, thereby amplifying the generation of cytokines, glutamate and nitric oxide. [12] . Finally, it is known that pro-inflammatory cytokines can, in turn, increase the expression of the amyloid precursor protein and its processing through amyloidogenic pathways [13] . In this way, A␤ accumulation may therefore establish a self-sustaining cycle whereby neuronal stress and glial activation foster an inflammatory response, which in turn promotes the synthesis and the accumulation of more A␤, thus perpetuating glial cell activation [14, 15] [16] . Among these molecules, palmitoylethanolamide (PEA) has attracted much attention for its proven anti-inflammatory and neuroprotective properties, as observed in many neuropathological conditions, mainly in the peripheral nervous system [17, 18] .
In addition, recent evidence reported the capability of A␤ to induce cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) synthesis in astrocytes through a NF-B dependent mechanism
PEA, a naturally occurring amide of ethanolamine and palmitic acid, is a lipid messenger that mimics several endocannabinoiddriven actions, even though it does not bind to cannabinoid receptors [18, 19] . PEA has been extensively studied for its antiinflammatory, analgesic, anti-epileptic and neuroprotective effects [20] [21] [22] [23] [24] [25] [26] [27] . It has also been reported to inhibit food intake [28] , to reduce gastrointestinal motility [29] , to counteract cancer cell proliferation [30, 31] and to protect the vascular endothelium in the ischemic heart [32] . Some of these properties have been considered to be dependent on the expression of peroxisome proliferator-activated receptor-␣ (PPAR-␣) [18, 33, 34] . PEA is abundant in the CNS and it is conspicuously produced by glial cells [35, 36] 
Materials and methods

Cell culture and treatments
All experiments were carried out in cultured primary astrocytes freshly isolated from newborn Sprague-Dawley rats (2 days old) according to Vairano et al. [37] . All A spectrophotometer assay based on the Griess reaction was used [38] . The absorbance of controls and unknown samples was measured at 540 nm. The NO2
Ϫ concentration was thus determined using a standard curve of sodium nitrite and referred to 1 ϫ 10 6 cells. (Fig. 1) . Likewise, both expression and release of S100B were investigated. S100B is an astroglia-derived protein which acts as a neurotrophic factor and neuronal survival protein, even though the overproduction of S100B by activated glia can lead to exacerbation of neuroinflammation and neuronal dysfunction. S100B levels generally correlate with the severity of damage and elevated levels of S100B are closely associated with a sustained reactive gliosis. Results from cultured astrocytes showed a significant increase in both expression and release of S100B protein after A␤ exposure, and these effects were counteracted by PEA. Once again this effect of PEA was partly reduced by MK886, suggesting a PPAR-␣ involvement (Fig. 1) .
Analysis of cytokine secretion
(A) Results of GFAP and S100B Western blot analysis and densitometric analysis of corresponding bands. ␤-actin was used as loading control. (B) Results of GFAP RT-PCR amplification and densitometric analysis of corresponding bands. GAPDH was used as standard control. (C) Measurement of S100B release by ELISA assay. (D) Analysis of GFAP and S100B protein expression by immunofluorescence (magnification 10ϫ
PEA blunts A␤-induced neuroinflammation
Another set of experiments was aimed at assessing the effect of PEA on the production of inflammatory factors induced by A␤. (Figs 2 and 3) .
tive PPAR-␥ antagonist (GW9662, 9 nM) or the selective PPAR-␣ antagonist (MK886, 3 M). iNOS and COX-2 protein expression was evaluated 24 hrs following treatments by Western blot and immunofluorescence analyses. After 24 hrs of A␤-challenge, it was evaluated the release in the cellular milieu of nitric oxide, measured as its stable metabolite NO2, and PGE2 by the Griess reaction and ELISA assay, respectively. (A) Results of iNOS and COX-2 Western blot analysis and densitometric analysis of corresponding bands. ␤-actin was used as loading control. (B) Determination of nitric oxide by the spectrophotometric assay based on the Griess reaction. (C) Measurement of PGE2 release by ELISA assay. (D) Analysis of iNOS and COX-2 protein expression by immunofluorescence (magnification 10ϫ
The anti-inflammatory actions of PEA depend upon MAPK inhibition
Further experiments were aimed at investigating whether the increase in the production of inflammatory factors induced by A␤ (Fig. 4) . Treatment of astrocytes with A␤ resulted in an increase in the level of phosphorylation of the kinases, and it was accompanied with the activation of the nuclear factor NF-B and AP-1, as shown by EMSA analysis (Fig. 5) (Fig. 6 ).
PEA modulates the A␤-induced alteration in PPAR transcription and expression
Additional experiments were aimed at investigating whether exposure to A␤ was able to affect PPAR transcription and expression. RT-PCR and Western blot analyses revealed that A␤ significantly down-regulated PPAR-␣, but not PPAR-␥, transcription and expression. In the same experimental conditions, PEA was able to counteract the above reported alterations induced by A␤
The endocannabinoid system in astrocytes treated with A␤ or PEA
When astrocytes were treated under the same conditions which lead to inflammation, an important increase in CB2 expression and a significant decrease in CB1 expression were observed (Fig. 7) . In addition, A␤ exposure induced a marked increase in astrocyte levels of the endocannabinoid 2-AG, the preferential agonist at CB2 receptor. Moreover, the peptide challenge resulted in a clear enhancement of PEA and OEA, both able to bind to PPPAR-␣. [41, 42] , as well as with the activation of the nuclear transcription factors NF-kB and AP-1. All these factors are responsible for the expression of many inflammatory mediators, thus fostering a detrimental cycle in which neuroinflammation induces a selfsustained process [43] [44] [45] [46] [47] [48] 
PPAR-␥ antagonist (GW9662, 9 nM) or the selective PPAR-␣ antagonist (MK886, 3 M). Nuclear transcription factors activation was evaluated after 30 min. of treatments by EMSA analysis. Figure shows the results of NF-B and AP-1 complex shifts (upper panel) and densitometric analysis of corresponding bands (lower panel). Treatment of astrocytes with A␤ induced the activation of the nuclear factors NF-B and AP-1 (lines 2). PEA significantly inhibited this effect (lines 3). This inhibition was attenuated by the PPAR-␣ antagonist, MK886, in a partial, although significant, manner (lines 5). Each bar shows the mean Ϯ S.E.M. of n
